Favorable long-term outcomes of endoscopic resection for nonampullary duodenal neuroendocrine tumor.
duodenum
endoscopic mucosal resection
neuroendocrine tumors
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
30
05
2021
received:
13
04
2021
accepted:
15
06
2021
pubmed:
19
6
2021
medline:
11
1
2022
entrez:
18
6
2021
Statut:
ppublish
Résumé
The long-term outcomes of endoscopic resection for nonampullary duodenal neuroendocrine tumors are limited. We aimed to clarify it. Consecutive patients with nonampullary duodenal neuroendocrine tumors endoscopically treated at our institute between January 2005 and June 2020 were included in this retrospective study. En bloc and R0 resection rates and adverse events were evaluated as short-term outcomes of endoscopic resection. The 5-year overall and recurrence-free survival rates of patients after endoscopic resection were calculated as long-term outcomes. Of 34 patients with 34 lesions, 33 patients (97%) underwent endoscopic mucosal resection, and one (3%) underwent endoscopic submucosal dissection. En bloc resection was achieved in 33 lesions (97%). R0 resection was achieved in 20 lesions (59%). The median tumor size was 6 mm (range: 3-13). Thirty-one lesions (91%) and three lesions (9%) were classified as G1 and G2, respectively. Lymphovascular invasion was observed in six lesions (18%). Intraprocedural perforation occurred in four patients (12%) who were conservatively treated with endoscopic closure. All 34 patients were followed up without additional treatment after endoscopic resection, and no recurrence or metastasis developed during the median follow-up period of 47.9 months (range: 9.0-187.1). The 5-year overall survival and recurrence-free survival rates were 87.1% and 100%, respectively. Endoscopic resection provided a favorable long-term prognosis for patients with nonampullary duodenal neuroendocrine tumors without lymph node metastasis.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The long-term outcomes of endoscopic resection for nonampullary duodenal neuroendocrine tumors are limited. We aimed to clarify it.
METHODS
METHODS
Consecutive patients with nonampullary duodenal neuroendocrine tumors endoscopically treated at our institute between January 2005 and June 2020 were included in this retrospective study. En bloc and R0 resection rates and adverse events were evaluated as short-term outcomes of endoscopic resection. The 5-year overall and recurrence-free survival rates of patients after endoscopic resection were calculated as long-term outcomes.
RESULTS
RESULTS
Of 34 patients with 34 lesions, 33 patients (97%) underwent endoscopic mucosal resection, and one (3%) underwent endoscopic submucosal dissection. En bloc resection was achieved in 33 lesions (97%). R0 resection was achieved in 20 lesions (59%). The median tumor size was 6 mm (range: 3-13). Thirty-one lesions (91%) and three lesions (9%) were classified as G1 and G2, respectively. Lymphovascular invasion was observed in six lesions (18%). Intraprocedural perforation occurred in four patients (12%) who were conservatively treated with endoscopic closure. All 34 patients were followed up without additional treatment after endoscopic resection, and no recurrence or metastasis developed during the median follow-up period of 47.9 months (range: 9.0-187.1). The 5-year overall survival and recurrence-free survival rates were 87.1% and 100%, respectively.
CONCLUSIONS
CONCLUSIONS
Endoscopic resection provided a favorable long-term prognosis for patients with nonampullary duodenal neuroendocrine tumors without lymph node metastasis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3329-3336Informations de copyright
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
Attanoos R, Williams GT. Epithelial and neuroendocrine tumors of the duodenum. Semin. Diagn. Pathol. 1991; 8: 149-162.
Fitzgerald TL, Dennis SO, Kachare SD, Vohra NA, Zervos EE. Increasing incidence of duodenal neuroendocrine tumors: incidental discovery of indolent disease? Surgery 2015; 158: 466-471.
Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract. Res. Clin. Gastroenterol. 2005; 19: 675-697.
Ito T, Igarashi H, Nakamura K et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J. Gastroenterol. 2015; 50: 58-64.
Scherübl H, Streller B, Stabenow R et al. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J. Gastroenterol. 2013; 19: 9012-9019.
Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008; 26: 3063-3072.
Delle Fave G, Kwekkeboom DJ, Van Cutsem E et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74-87.
Delle Fave G, O'Toole D, Sundin A et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016; 103: 119-124.
Hatta W, Koike T, Iijima K et al. The risk factors for metastasis in non-ampullary duodenal neuroendocrine tumors measuring 20 mm or less in diameter. Digestion 2017; 95: 201-209.
Park SG, Lee BE, Kim GH et al. Risk factors for lymph node metastasis in duodenal neuroendocrine tumors: a retrospective, single-center study. Medicine (Baltimore) 2019; 98: e15885.
Weatherall T, Denbo J, Sharpe J et al. Well-differentiated, non-functional, non-ampullary duodenal neuroendocrine tumors: toward defining evaluation and management. World J. Surg. 2017; 41: 844-850.
Zhang XF, Wu XN, Tsilimigras DI et al. Duodenal neuroendocrine tumors: impact of tumor size and total number of lymph nodes examined. J. Surg. Oncol. 2019; 120: 1302-1310.
Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann. Surg. 2006; 244: 10-15.
Cherif R, Gaujoux S, Couvelard A et al. Parenchyma-sparing resections for pancreatic neuroendocrine tumors. J. Gastrointest. Surg. 2012; 16: 2045-2055.
Gervais DA, Fernandez-del Castillo C, O'Neill MJ, Hahn PF, Mueller PR. Complications after pancreatoduodenectomy: imaging and imaging-guided interventional procedures. Radiographics 2001; 21: 673-690.
Klein A, Ahlenstiel G, Tate DJ et al. Endoscopic resection of large duodenal and papillary lateral spreading lesions is clinically and economically advantageous compared with surgery. Endoscopy 2017; 49: 659-667.
Sachs TE, Tseng JF. Landmark series in pancreatic tumors: anastomotic techniques and route of reconstruction. Ann. Surg. Oncol. 2021; 28: 2227-2234.
Gincul R, Ponchon T, Napoleon B et al. Endoscopic treatment of sporadic small duodenal and ampullary neuroendocrine tumors. Endoscopy 2016; 48: 979-986.
Kim GH, Kim JI, Jeon SW et al. Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study. J. Gastroenterol. Hepatol. 2014; 29: 318-324.
Nagtegaal ID, Odze RD, Klimstra D et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182-188.
Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 2005; 46: 396-402.
Kitagawa Y, Ikebe D, Hara T et al. Enhanced detection of lymphovascular invasion in small rectal neuroendocrine tumors using D2-40 and Elastica van Gieson immunohistochemical analysis. Cancer Med. 2016; 5: 3121-3127.
Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J. Histochem. Cytochem. 2006; 54: 385-395.
Park CH, Cheon JH, Kim JO et al. Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy 2011; 43: 790-795.
Downs-Canner S, Van der Vliet WJ, Thoolen SJJ et al. Robotic surgery for benign duodenal tumors. J. Gastrointest. Surg. 2015; 19: 306-312.
Mashimo Y, Matsuda T, Uraoka T et al. Endoscopic submucosal resection with a ligation device is an effective and safe treatment for carcinoid tumors in the lower rectum. J. Gastroenterol. Hepatol. 2008; 23: 218-221.
Nagai T, Torishima R, Nakashima H et al. Saline-assisted endoscopic resection of rectal carcinoids: cap aspiration method versus simple snare resection. Endoscopy 2004; 36: 202-205.
Ono A, Fujii T, Saito Y et al. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest. Endosc. 2003; 57: 583-587.
Shroff SR, Kushnir VM, Wani SB et al. Efficacy of endoscopic mucosal resection for management of small duodenal neuroendocrine tumors. Surg. Laparosc. Endosc. Percutan. Tech. 2015; 25: e134-e139.
Nishio M, Hirasawa K, Ozeki Y et al. Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors. Ann. Gastroenterol. 2020; 33: 265-271.
Lee SW, Sung JK, Cho YS et al. Comparisons of therapeutic outcomes in patients with nonampullary duodenal neuroendocrine tumors (NADNETs): a multicenter retrospective study. Medicine (Baltimore) 2019; 98: e16154.
Park SB, Kang DH, Choi CW, Kim HW, Kim SJ. Clinical outcomes of ligation-assisted endoscopic resection for duodenal neuroendocrine tumors. Medicine (Baltimore) 2018; 97: e0533.
Soga J. Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases. J. Exp. Clin. Cancer Res. 2003; 22: 349-363.
Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Management of early gastrointestinal neuroendocrine neoplasms. World J. Gastrointest. Endosc. 2011; 3: 133-139.
Untch BR, Bonner KP, Roggin KK et al. Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. J. Gastrointest. Surg. 2014; 18: 457-462 discussion 62-63.
Vanoli A, La Rosa S, Klersy C et al. Four neuroendocrine tumor types and neuroendocrine carcinoma of the duodenum: analysis of 203 cases. Neuroendocrinology 2017; 104: 112-125.
Wang R, Mohapatra S, Jovani M et al. Risk factors for lymph node metastasis and survival of patients with nonampullary duodenal carcinoid tumors treated with endoscopic therapy versus surgical resection: analysis of the surveillance, epidemiology, and end results program. Gastrointest. Endosc. 2021; 93: 1384-1392.